Australia Stock Exchange release from RACE ONCOLOGY LT : MD Anderson Preclinical AML Study on Zantrene Published
22/02/2022 22:39
Australia Stock Exchange release from RACE ONCOLOGY LT RAC.AX : MD Anderson Preclinical AML Study on Zantrene Published
Recent news on Racura Oncology
See all newsAustralia's Racura Oncology jumps most in a month after raising $24 million
Brief: Racura Oncology Says Emerging Companies Specialist Invests In Racura
Brief: Racura Oncology Announces Positive Safety Review Committee Recommendation In Ongoing Cpacs Clinical Trial
Australia's Racura Oncology gains on Purdue University cancer study collab
Brief: Racura Oncology Receives Governance Approval For Harness-1 Phase 1 Trial Of Rc220